Effect of N-Acetylcysteine on Residual Renal Function in Chronic Haemodialysis Patients Treated with High-Flux Synthetic Dialysis Membranes: A Pilot Study
Table 2
Effect of N-acetylcysteine on clinical characteristics and residual renal function, mean (±SD).
Treatment group
Control group
Baseline
NAC therapy
Baseline
NAC therapy
Predialysis weight, kg
75.2 ± 13.1
75.7 ± 12.9
82.1 ± 14.9
82.2 ± 15.3
Systolic BP, mmHg
140.8 ± 18.1
142.7 ± 12.2
136.0 ± 19.1
138.2 ± 18.3
Diastolic BP, mmHg
71.3 ± 16.8
73.7 ± 16.2
70.7 ± 16.2
69.3 ± 12.9
Ultrafiltration on dialysis session, L
2.7 ± 0.26
2.4 ± 0.62
2.6 ± 0.89
2.7 ± 0.86
Urine volume, mL/24 h
268 ± 174
313 ± 185
366 ± 203
497 ± 242
Kt/V renal (per week)
0.25 ± 0.23
0.32 ± 0.24
0.21 ± 0.11
0.33 ± 0.14
Residual GFR, mL/min/1.73 m²
1.61 ± 1.36
1.78 ± 1.59
1.53 ± 0.88
2.18 ± 1.12
Residual GFR change, mL/min/1.73 m²
NA
+0.17 ± 0.56
NA
+0.65 ± 0.53*
Serum NO, mcmol/L
35.1 ± 28.6
34.6 ± 15.0
61.8 ± 68.5
58.2 ± 60.4
Serum ADMA, mcmol/L
0.54 ± 0.24
0.53 ± 0.19
0.91 ± 0.20
0.93 ± 0.18
NAC: N-acetylcysteine; BP: blood pressure; GFR: glomerular filtration rate; NO: nitric oxide; ADMA: asymmetric dimethylarginine.
*
P < 0.05 versus corresponding value. NA: not applicable.
